Press releaseGlobe Newswire
Exscientia
EXAI · NASDAQ
Price unavailable right now.
No price history for this range.
Latest news
- Press releaseGlobe Newswire
Recursion and Exscientia Shareholders Approve the Proposed Combination
- Press releaseBusiness Wire
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
- Press releaseBusiness Wire
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
- Press releaseBusiness Wire
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
- Press releasePRNewswire
AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom
- Press releaseBusiness Wire
Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Press releaseBusiness Wire
Exscientia Business Update for Second Quarter and First Half 2024
- Press releaseGlobe Newswire
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
- NewsVandana Singh
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
- Press releaseGlobe Newswire
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
- Press releasePRNewswire
Latest Updates of Viva Biotech's Portfolio Companies
- Press releaseBusiness Wire
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.